Verdalia Acquires Five Biomethane Plants in Northern Italy

Verdalia Bioenergy, a European biomethane company supported by Goldman Sachs Alternatives infrastructure funds, has reached an agreement for the acquisition of 5 greenfield biomethane plants in Italy from funds controlled by Green Arrow Capital, one of the leading independent Italian operators in the alternative investment landscape, and by Lazzari&Lucchini, a company specialized in energy production.

The transaction follows Verdalia’s recent acquisitions of 7 plants operational in May 2024 and 4 greenfield projects in August 2024 in neighboring areas of Northern Italy

Launched in February 2023 with the aim of investing at least €1 billion in the development, acquisition and operation of biomethane production plants in Europe by 2026, Verdalia Bioenergy has made significant progress in Italy, becoming one of the leading operators in the field of agricultural biomethane plants, with a team of over 90 people between Spain and Italy and a pipeline of projects under development of over 2.5 TWh per year.

The portfolio consists of 5 plants in an advanced stage of development and located in Lombardy and Veneto, with an overall expected production capacity of approximately 170 GW per year of biomethane deriving from the treatment of 250,000 tons of raw materials per year. The plants are scheduled to be commissioned by the end of 2025, with biomethane production coming exclusively from the processing of animal waste and agricultural waste not intended for human consumption.

The plants acquired by Verdalia are scheduled to be operational by the end of 2025, with biomethane production coming from the processing of animal waste and agricultural waste not intended for human consumption. The portfolio, once operational, will have the goal of reducing the equivalent of 50,000 tons of greenhouse gas emissions per year.

__

(Featured image by RoboAdvisor via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in ESG NEWS. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us